By: Editorial Staff, Date: October 18th, 2024
The Hatch-Waxman Act has effectively fostered competition in the pharmaceutical market by streamlining the approval process for generic drugs while balancing the need for innovation among brand-name manufacturers. Discover how the Hatch-Waxman Act has transformed access to affordable medicines and reshaped the pharmaceutical industry in this infographic.
Discover more insights at our webcast: Hatch-Waxman Case-Law Developments and New Jersey Practice Insights
Upcoming Webcasts
FINRA Arbitration: Current Issues and Practice Tips for 2023
Following the controversial ruling by Georgia State Court on the Wells Fargo arbitration award in 2022, the Financial Industry Regulatory Authority (FINRA) is now pushing for a more transparent arbitration procedure. FINRA's new proposed rule change with the Securities and Exchange Commission (SEC) is aimed at improving the prevailing practices in the arbitration and resolution forum. While the FINRA arbitration landscape remains uncertain until the approved rule changes, practitioners must keep themselves abreast of any developments to mitigate potential drawbacks.